Please use this identifier to cite or link to this item:
|Title:||Gut microbiota - a double-edged sword in cancer immunotherapy.||Austin Authors:||Andrews, Miles C;Vasanthakumar, Ajithkumar||Affiliation:||Department of Medicine - Alfred, Monash University, Melbourne, Victoria, Australia.
Olivia Newton-John Cancer Research Institute
La Trobe University, Bundoora, Victoria, Australia
|Issue Date:||2023||Date:||2022||Publication information:||Trends in Cancer 2023; 9(1)||Abstract:||Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making manipulation of the microbiome a novel therapeutic strategy with which to improve ICB outcomes.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30858||DOI:||10.1016/j.trecan.2022.08.003||Journal:||Trends in Cancer||PubMed URL:||36088249||Type:||Journal Article|
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.